Enfusion (ENFN)
(Delayed Data from NYSE)
$8.42 USD
-0.31 (-3.55%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $8.41 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ENFN 8.42 -0.31(-3.55%)
Will ENFN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ENFN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENFN
Implied Volatility Surging for Enfusion (ENFN) Stock Options
Enfusion (ENFN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
ENFN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Enfusion, Inc. (ENFN) Q2 Earnings and Revenues Miss Estimates
STNE or ENFN: Which Is the Better Value Stock Right Now?
Implied Volatility Surging for Enfusion (ENFN) Stock Options
Other News for ENFN
Enfusion: Growth Should Accelerate In Coming Quarters
Enfusion, Inc. (ENFN) Q2 2024 Earnings Call Transcript
Morgan Stanley Keeps Their Buy Rating on Enfusion (ENFN)
Enfusion Inc (ENFN) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...
ENFN Stock Earnings: Enfusion Misses EPS, Misses Revenue for Q2 2024